Please assess the completion status of the following clinical trial:

Trial Title: Effect of Veramyst and Olopatadine 0.2% Opthalmic Solution on Allergy Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and females between 18 and 45 years of age.~2. History of grass and/or ragweed allergic rhinitis.~3. Positive skin test to grass and/or ragweed antigen.~4. Positive response to screening nasal challenge.~Exclusion Criteria:~1. Physical signs or symptoms suggestive of renal, hepatic or cardiovascular disease.~2. Pregnant or lactating women.~3. Upper respiratory infection within 14 days of study start.~4. forced expiratory volume at one second (FEV1) \<80% of predicted at screening for subjects with history of mild asthma.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- FF/PL, PL/OLO, FF/OLO, PL/PL (Type: OTHER): Each subject received a total of 4 weeks of treatment (1 week per treatment with 2 week washout period between treatments) in the following order:~* fluticasone furoate (FF) nasal spray and PL eye drops (FF/PL)~* PL nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (PL/OLO),~* FF nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (FF/OLO), and~* placebo (PL) nasal spray and PL eye drops (PL/PL).
- PL/OLO, FF/OLO, PL/PL, FF/PL (Type: OTHER): Each subject received a total of 4 weeks of treatment (1 week per treatment with 2 week washout period between treatments) in the following order:~* PL nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (PL/OLO),~* FF nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (FF/OLO),~* placebo (PL) nasal spray and PL eye drops (PL/PL), and~* fluticasone furoate (FF) nasal spray and PL eye drops (FF/PL).
- FF/OLO, PL/PL, FF/PL, PL/OLO (Type: OTHER): Each subject received a total of 4 weeks of treatment (1 week per treatment with 2 week washout period between treatments) in the following order:~* FF nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (FF/OLO),~* placebo (PL) nasal spray and PL eye drops (PL/PL),~* fluticasone furoate (FF) nasal spray and PL eye drops (FF/PL), and~* PL nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (PL/OLO).
- PL/PL, FF/PL, PL/OLO, FF/OLO (Type: OTHER): Each subject received a total of 4 weeks of treatment (1 week per treatment with 2 week washout period between treatments) in the following order:~* placebo (PL) nasal spray and PL eye drops (PL/PL),~* fluticasone furoate (FF) nasal spray and PL eye drops (FF/PL),~* PL nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (PL/OLO), and~* FF nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (FF/OLO).

Based on this trial design, predict the completion outcome and termination type (if applicable).